Insulet (PODD) Stock Forecast & Price Target

Compare

963 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PODD Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Insulet

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PODD Stock 12 Month Forecast

Average Price Target

$377.06

▲(13.07% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $377.06 with a high forecast of $428.00 and a low forecast of $301.00. The average price target represents a 13.07% change from the last price of $333.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"234":"$234","429":"$429","282.75":"$282.8","331.5":"$331.5","380.25":"$380.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":428,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$428.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":377.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$377.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":301,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$301.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[234,282.75,331.5,380.25,429],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.01,321.8553846153846,330.7007692307692,339.54615384615386,348.39153846153846,357.23692307692306,366.08230769230767,374.92769230769227,383.7730769230769,392.61846153846153,401.46384615384613,410.3092307692308,419.15461538461534,{"y":428,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.01,317.93692307692305,322.86384615384617,327.79076923076923,332.7176923076923,337.6446153846154,342.57153846153847,347.4984615384615,352.4253846153846,357.3523076923077,362.27923076923076,367.2061538461538,372.13307692307694,{"y":377.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.01,312.0861538461538,311.1623076923077,310.23846153846154,309.31461538461537,308.39076923076925,307.4669230769231,306.5430769230769,305.61923076923074,304.6953846153846,303.77153846153846,302.8476923076923,301.92384615384617,{"y":301,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":235.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":261.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":344.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$428.00

Average Price Target$377.06

Lowest Price Target$301.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Antalffy

UBS

$355→$400

Buy

19.95%

Upside

Upgraded

11/19/25

Insulet's Strong Growth Potential and Competitive Edge Drive Buy Rating

Marie Thibault

BTIG

$370

Buy

10.95%

Upside

Reiterated

11/13/25

Insulet's Promising Growth and Strategic Initiatives Earn a Buy Rating from Marie ThibaultValuation: Our Insulet rating is Buy. Our $370 price target is based on ~7.5x our 12-24 month sales estimate.

Travis Steed

Bank of America Securities

$360

Buy

7.96%

Upside

Reiterated

11/12/25

Insulet's Strategic Growth and Innovation Drive Buy Rating

Richard Newitter

Truist Financial

$365→$390

Buy

16.95%

Upside

Reiterated

11/07/25

Insulet (PODD) Receives a Buy from Truist Financial

Matthew Taylor

Jefferies

$375→$400

Buy

19.95%

Upside

Reiterated

11/07/25

Insulet's Strong Sales and Strategic Growth Drive Buy RatingWe are encouraged by the result, momentum in new customer starts, and the T2 pickup and view 4Q guidance as conservative. We continue to like shares of PODD into the analyst day and healthy '26 setup. Raising #s and PT; reit. Buy. PODD reported 3Q Omnipod sales of $699MM +29.3% xfx (cons $677MM), +28% comp adjusted, with US sales of $497MM +25.6% (vs cons $486MM) and OUS sales of $202MM +39.9% xfx (vs cons $189MM). This was another record qtr of new customer starts (NCS), which grew y/y and q/ q, and the second consecutive quarter of the highest competitive conversions since late '23, along with ongoing MDI wins (>85% of NCS), and acceleration in T2 (>35% of US NCS). GM of 72.2% (+290bps y/y) was fueled by top line leverage and ongoing price/mix TWs + scale efficiencies.

Larry Biegelsen

Wells Fargo

$350→$360

Buy

7.96%

Upside

Reiterated

11/07/25

Insulet price target raised to $360 from $350 at Wells FargoInsulet price target raised to $360 from $350 at Wells Fargo

Jonathan Block

Stifel Nicolaus

$370

Buy

10.95%

Upside

Reiterated

11/07/25

Stifel Nicolaus Sticks to Its Buy Rating for Insulet (PODD)

Lee Hambright

Bernstein

$400→$410

Buy

22.95%

Upside

Assigned

11/07/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Alnylam Pharma (NASDAQ: ALNY) and Insulet (NASDAQ: PODD)

William Plovanic

Canaccord Genuity

$399→$428

Buy

28.35%

Upside

Reiterated

11/07/25

Insulet price target raised to $428 from $399 at CanaccordInsulet price target raised to $428 from $399 at Canaccord

Lila Implantra

TR | OpenAI - 4o

$349→$367

Buy

10.05%

Upside

Reiterated

11/07/25

AI Generated ArticleAI Generated Article

Shagun Singh Chadha

RBC Capital

$365→$370

Buy

10.95%

Upside

Reiterated

11/06/25

Insulet (PODD) Gets a Buy from RBC Capital

Josh Jennings

TD Cowen

$379

Buy

13.65%

Upside

Reiterated

11/06/25

Insulet's Strong Financial Performance and Growth Prospects Earn Buy Rating from AnalystWe expect its momentum to remain strong, driven by the T2 ramp, further T1 penetration and global expansion.

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

11/06/25

Insulet's Strong Q3 Performance and International Expansion Drive Buy Rating

Matt Miksic

Barclays

$300→$301

Hold

-9.74%

Downside

Reiterated

11/04/25

Barclays Sticks to Their Hold Rating for Insulet (PODD)

Mike Kratky

Leerink Partners

$339→$355

Buy

6.46%

Upside

Reiterated

10/14/25

Leerink Partners Keeps Their Buy Rating on Insulet (PODD)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Antalffy

UBS

$355→$400

Buy

19.95%

Upside

Upgraded

11/19/25

Insulet's Strong Growth Potential and Competitive Edge Drive Buy Rating

Marie Thibault

BTIG

$370

Buy

10.95%

Upside

Reiterated

11/13/25

Insulet's Promising Growth and Strategic Initiatives Earn a Buy Rating from Marie ThibaultValuation: Our Insulet rating is Buy. Our $370 price target is based on ~7.5x our 12-24 month sales estimate.

Travis Steed

Bank of America Securities

$360

Buy

7.96%

Upside

Reiterated

11/12/25

Insulet's Strategic Growth and Innovation Drive Buy Rating

Richard Newitter

Truist Financial

$365→$390

Buy

16.95%

Upside

Reiterated

11/07/25

Insulet (PODD) Receives a Buy from Truist Financial

Matthew Taylor

Jefferies

$375→$400

Buy

19.95%

Upside

Reiterated

11/07/25

Larry Biegelsen

Wells Fargo

$350→$360

Buy

7.96%

Upside

Reiterated

11/07/25

Insulet price target raised to $360 from $350 at Wells FargoInsulet price target raised to $360 from $350 at Wells Fargo

Jonathan Block

Stifel Nicolaus

$370

Buy

10.95%

Upside

Reiterated

11/07/25

Stifel Nicolaus Sticks to Its Buy Rating for Insulet (PODD)

Lee Hambright

Bernstein

$400→$410

Buy

22.95%

Upside

Assigned

11/07/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Alnylam Pharma (NASDAQ: ALNY) and Insulet (NASDAQ: PODD)

William Plovanic

Canaccord Genuity

$399→$428

Buy

28.35%

Upside

Reiterated

11/07/25

Insulet price target raised to $428 from $399 at CanaccordInsulet price target raised to $428 from $399 at Canaccord

Lila Implantra

TR | OpenAI - 4o

$349→$367

Buy

10.05%

Upside

Reiterated

11/07/25

AI Generated ArticleAI Generated Article

Shagun Singh Chadha

RBC Capital

$365→$370

Buy

10.95%

Upside

Reiterated

11/06/25

Insulet (PODD) Gets a Buy from RBC Capital

Josh Jennings

TD Cowen

$379

Buy

13.65%

Upside

Reiterated

11/06/25

Insulet's Strong Financial Performance and Growth Prospects Earn Buy Rating from AnalystWe expect its momentum to remain strong, driven by the T2 ramp, further T1 penetration and global expansion.

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

11/06/25

Insulet's Strong Q3 Performance and International Expansion Drive Buy Rating

Matt Miksic

Barclays

$300→$301

Hold

-9.74%

Downside

Reiterated

11/04/25

Barclays Sticks to Their Hold Rating for Insulet (PODD)

Mike Kratky

Leerink Partners

$339→$355

Buy

6.46%

Upside

Reiterated

10/14/25

Leerink Partners Keeps Their Buy Rating on Insulet (PODD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insulet

1 Month

xxx

Success Rate

12/18 ratings generated profit

Average Return

+5.32%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.32% per trade.

3 Months

xxx

Success Rate

17/18 ratings generated profit

Average Return

+13.74%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 94.44% of your transactions generating a profit, with an average return of +13.74% per trade.

1 Year

Matthew TaylorJefferies

Success Rate

17/18 ratings generated profit

Average Return

+33.53%

reiterated a buy rating 13 days ago

Copying Matthew Taylor's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +33.53% per trade.

2 Years

xxx

Success Rate

23/23 ratings generated profit

Average Return

+80.37%

upgraded a xxx

rating 22 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +80.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PODD Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PODD has received 31 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. PODD average Analyst price target in the past 3 months is 377.06.

Each month's total comprises the sum of three months' worth of ratings.

PODD Financial Forecast

PODD Earnings Forecast

Next quarter’s earnings estimate for PODD is $1.45 with a range of $1.32 to $1.86. The previous quarter’s EPS was $1.24. PODD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year PODD has Performed in-line its overall industry.

PODD Sales Forecast

Next quarter’s sales forecast for PODD is $768.26M with a range of $755.60M to $778.00M. The previous quarter’s sales results were $706.30M. PODD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year PODD has Performed in-line its overall industry.

PODD Stock Forecast FAQ

What is PODD’s average 12-month price target, according to analysts?

Based on analyst ratings, Insulet’s 12-month average price target is 377.06.

What is PODD’s upside potential, based on the analysts’ average price target?

Insulet has 13.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PODD a Buy, Sell or Hold?

Insulet has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is Insulet’s price target?

The average price target for Insulet is 377.06. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $428.00 ,the lowest forecast is $301.00. The average price target represents 13.07% Increase from the current price of $333.47.

What do analysts say about Insulet?

Insulet’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of PODD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Insulet (PODD) Stock Forecast & Price Target

PODD Analyst Ratings

PODD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insulet

PODD Analyst Recommendation Trends

PODD Financial Forecast

PODD Earnings Forecast

PODD Sales Forecast

PODD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts